Bian Chang, Wang Yu, Lu Zhihao, An Yu, Wang Hanfan, Kong Lingxin, Du Yang, Tian Jie
CAS Key Laboratory of Molecular Imaging, The State Key Laboratory of Management and Control for Complex Systems, Institute of Automation, Chinese Academy of Sciences, Beijing 100190, China.
School of Artificial Intelligence, University of Chinese Academy of Sciences, Beijing 100049, China.
Cancers (Basel). 2021 Apr 1;13(7):1659. doi: 10.3390/cancers13071659.
Spatial distribution of tumor infiltrating lymphocytes (TILs) and cancer cells in the tumor microenvironment (TME) along with tumor gene mutation status are of vital importance to the guidance of cancer immunotherapy and prognoses. In this work, we developed a deep learning-based computational framework, termed ImmunoAIzer, which involves: (1) the implementation of a semi-supervised strategy to train a cellular biomarker distribution prediction network (CBDPN) to make predictions of spatial distributions of CD3, CD20, PanCK, and DAPI biomarkers in the tumor microenvironment with an accuracy of 90.4%; (2) using CBDPN to select tumor areas on hematoxylin and eosin (H&E) staining tissue slides and training a multilabel tumor gene mutation detection network (TGMDN), which can detect APC, KRAS, and TP53 mutations with area-under-the-curve (AUC) values of 0.76, 0.77, and 0.79. These findings suggest that ImmunoAIzer could provide comprehensive information of cell distribution and tumor gene mutation status of colon cancer patients efficiently and less costly; hence, it could serve as an effective auxiliary tool for the guidance of immunotherapy and prognoses. The method is also generalizable and has the potential to be extended for application to other types of cancers other than colon cancer.
肿瘤微环境(TME)中肿瘤浸润淋巴细胞(TILs)和癌细胞的空间分布以及肿瘤基因突变状态对于癌症免疫治疗的指导和预后至关重要。在这项工作中,我们开发了一种基于深度学习的计算框架,称为ImmunoAIzer,它包括:(1)实施一种半监督策略来训练细胞生物标志物分布预测网络(CBDPN),以预测肿瘤微环境中CD3、CD20、PanCK和DAPI生物标志物的空间分布,准确率达90.4%;(2)使用CBDPN在苏木精和伊红(H&E)染色的组织切片上选择肿瘤区域,并训练一个多标签肿瘤基因突变检测网络(TGMDN),该网络可以检测APC、KRAS和TP53突变,曲线下面积(AUC)值分别为0.76、0.77和0.79。这些发现表明,ImmunoAIzer可以高效且低成本地提供结肠癌患者细胞分布和肿瘤基因突变状态的全面信息;因此,它可以作为指导免疫治疗和预后的有效辅助工具。该方法具有通用性,有可能扩展应用于结肠癌以外的其他类型癌症。